^
Association details:
| Biomarker: | High NLR |
|---|---|
| Cancer: | Breast Cancer |
| Drug Class: | CDK4 inhibitor + CDK6 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
Published date:
12/02/2023
Excerpt:
High MLR (p = 0.001) and high NLR (p = 0.01) at baseline significantly correlated with a shorter progression-free survival (PFS) in the CDK4/6i cohort, independent of any other clinical parameter as determined by multivariate Cox regression. Both, high MLR (p = 0.008) and high NLR (p = 0.043) as well as a decrease in PLR after four weeks of CDK4/6i first line treatment (p = 0.01) indicated a shorter overall survival....Most importantly, the imbalance of NLR and MLR at baseline might serve as predictive marker for de novo resistance to CDK4/6i in mBC patients.
DOI:
10.1038/s41598-023-47874-3
